Lantheus (LNTH) 10-Q2024 Q2 Quarterly report

Filed: 31 Jul 24, 7:50am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: addressable, adhere, advocacy, affiliate, alleging, Amyloid, antibody, anticancer, anticipate, approach, Aprinoia, arbitration, artery, assembled, attempt, attention, attract, AUC, aware, bargaining, beneficial, beta, Bioscience, blood, Blue, bombesin, Bracco, breast, Bristol, broadly, bundle, bundled, BWXT, calcium, cease, ceasing, cell, certified, choosing, colorectal, companion, compete, competing, competitor, complex, confirmed, consuming, coronary, costly, CT, cut, CY, damage, Denial, deny, detriment, difficulty, directly, diversified, divert, Earth, effectuate, employee, Endocycte, endorsed, evolve, evolving, family, found, Foundation, frame, freestanding, gastric, GRPR, harm, heart, HHS, highly, inability, indefinite, inhibition, inpatient, intense, interpretation, intracellular, introduction, invoice, invoicing, ITM, lack, larger, lawsuit, legacy, legislation, legislative, lesser, listed, lobby, longtime, lose, lung, meaningful, mechanism, Med, Meilleur, methodology, minimal, misappropriated, monoclonal, MRI, Myocardial, nanobody, nationwide, NCD, NDA, neurology, obsolete, operationalize, Orano, Orphan, osteosarcoma, ovarian, overexpressed, overexpressing, oversight, pair, pancreatic, pause, Perfusion, physician, play, poor, preclinical, predicated, preferred, prevent, promulgated, Purdue, put, qualification, radiodiagnostic, Radiopharm, Radiopharma, rapidly, Rare, RayzeBio, recission, reconcile, rendered, resistance, resume, reverse, scientific, serve, shareholder, shift, shifting, shipping, showed, signal, skilled, Sofie, split, statute, superior, surface, tangible, Telix, Thrall, timeline, train, transducer, treble, Trophoblast, tumor, turn, unable, unclear, uneconomical, unsuccessful, verify, violated, withdrawn

Removed: anatomical, ARROW, assessing, Biopharma, broader, choice, clearance, collected, Conformity, design, detection, displayed, expiring, facilitating, fibroblast, formulation, generation, geopolitical, half, inception, localization, marking, molecule, pandemic, presentation, quantification, reading, room, RT, Samsung, segmentation, shipment, small, soft, storage, temperature, tissue, updated, version

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated LNTH transcripts

LNTH similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Brian Markison, the Chief Executive Officer, and Robert J. Marshall, Jr., the Chief Financial Officer, of Lantheus Holdings, Inc. (the “Company”), hereby certify, that, to their knowledge:

1.The Quarterly Report on Form 10-Q for the period ended June 30, 2024 (the “Report”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: July 31, 2024



						/s/ BRIAN MARKISON
Name:						Brian Markison
Title:						Chief Executive Officer
						(Principal Executive Officer)

Date: July 31, 2024



						/s/ ROBERT J. MARSHALL, JR.
Name:						Robert J. Marshall, Jr.
Title:						Chief Financial Officer and Treasurer
						(Principal Financial Officer)

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.